I rritable bowel syndrome (IBS) is a chronic functional bowel disorder that is a major public health problem affecting 10%-15% of adults worldwide. 1 The morbidity associated with IBS places a huge financial burden on both the healthcare system and workplace and significantly impairs patients' quality of life. 2 The pathogenesis of IBS is multifactorial, although the gut microbiota is thought to play a pivotal role. 3 Some patients with IBS have intestinal dysbiosis characterized by a loss of microbial diversity, especially in those with diarrhea-predominant IBS (IBS-D). 4 Moreover, gut microbiota transplants from patients have been shown to induce an IBS-like disorder in mice. 5 The gut microbiota has also been used to predict IBS severity. 6 Nonetheless, the microbiota is currently an unrealistic diagnostic target or predictor of treatment outcome in practice because of the costs of its measurement. 7 Evidence suggests that microbial function as opposed to composition may better predict clinical outcome. 8 This is supported by research demonstrating that the fecal metabolome provides useful insight into IBS pathophysiology. More specifically, patterns of volatile organic compounds (VOCs) were able to separate patients with IBS, inflammatory bowel disease, and healthy controls with excellent accuracy. 9 This research has been validated by using both gas chromatography-mass spectrometry (GC-MS), 10 which is considered the gold standard technique, and a new GC-sensor approach. 9 This validates the potential for VOC as a diagnostic biomarker for IBS and supports the contention that IBS is associated with abnormal microbial metabolism.
There is currently no universal treatment for IBS. Pharmaceutical and dietary interventions have some efficacy for the management of gastrointestinal symptoms, although the latter encourages self-management. Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has been shown to significantly improve gastrointestinal symptoms in 50%-80% of patients with IBS. 11, 12 Nonetheless, the low FODMAP diet (LFD) has several limitations, including nutritional and microbiological sequelae and the labor-intensive and complex nature of the diet. 13 Probiotic supplementation has also shown some efficacy in IBS, although cost-to-benefit analysis limits widespread uptake. 14 Personalized nutrition is an emerging concept whereby dietary intervention is based on specific phenotypes (eg, blood markers) or genotype (eg, single nucleotide polymorphisms). 15 Identifying an appropriate phenotypic and genotypic biomarker is pivotal to the success of personalized nutrition. Because of the promising application of VOC as a diagnostic tool in IBS coupled with the fact that dietary interventions (LFD and probiotics) specifically target the gut microbiota, it is conceivable that fecal VOC may have a role in predicting response. Therefore, this exploratory study aimed to investigate whether a noninvasive diagnostic model using fecal VOC could be used to identify features associated with response to dietary intervention in IBS.
Materials and Methods
Our hypothesis was that specific VOC signatures at baseline would be able to predict response to LFD and probiotic interventions further, the VOC signatures at follow-up would differ between responders and nonresponders. To test these hypotheses, VOC profiles in baseline and end-of-treatment (4 weeks) fecal samples were analyzed from a 2 Â 2 factorial, multicenter, randomized, placebo-controlled trial of LFD and probiotics in the management of IBS. 16 
Clinical Trial
The current analysis used clinical data and stool samples from a clinical trial, the methods of which are described in full elsewhere. 16 Briefly, adults with IBS-D, mixed subtype IBS (IBS-M), or unsubtyped irritable bowel syndrome (IBS-U) according to Rome III criteria with no other major medical conditions were recruited from clinics at 2 hospitals in London, United Kingdom. Exclusion criteria were change to IBS medication, bowel preparation, and antibiotic therapy, prebiotics, or probiotics during the previous 4 weeks. Research ethics committee approval for the trial and for VOC analysis was received from the London Fulham Research Ethics Committee (Reference 12/LO/1402), and patients gave informed consent before participation.
Patients were randomized to both diet (sham or LFD) and supplement (placebo or probiotic) groups, stratified by gender and diagnosis of IBS-D, for 4 weeks. Patients were masked to both diet and supplement allocations. The researcher who provided the dietary advice was not masked to diet allocation but was masked to supplement allocation. The placebo and probiotic supplements were identical in appearance, taste, and presentation. Details of the dietary interventions are described in Supplementary Materials.
Symptoms were measured at baseline and follow-up by using the IBS Symptom Scoring System (IBS-SSS). 17 Patients with a change of <50 on the IBS-SSS were defined as non-responders. Further details of choice of clinical outcomes are described in Supplementary Materials. Differences in response rates between the diet and supplement groups were determined using c 2 , and differences in FODMAP intake between groups were determined using linear regression. Sensitivity analyses were undertaken to determine whether there was a significant interaction between the diet and supplement interventions. The null hypothesis was rejected at the 0.05 level. Statistical analyses of the clinical and dietary end points were performed using Stata (version 12, 2012; StataCorp, College Station, TX).
Volatile Organic Compound Analysis
At baseline and follow-up a whole fresh fecal sample was collected within 1 hour of passage, stored immediately on ice, homogenized in a Stomacher machine, and stored at -80 C until analysis. Samples were shipped on dry ice to the Sensor Laboratory, where they were stored at -20 C. Subsequently, 750-mg aliquots were analyzed by an in-house platform involving a GC sensor device (Odoreader) and a computer pipeline for pattern recognition and sample classification. 9, 18 A detailed description of the hardware and software used by the Odoreader has been published previously. 18 Briefly, each sample was heated to 50 C for 10 minutes, resulting in the release of VOCs from the feces and their accumulation at the headspace of the vial. A total of 2 cm 3 of its headspace was collected and injected into the GC column of the Odoreader. 19 The 30 m SPB-1 sulphur GC column (Supelco; Sigma-Aldrich, St Louis, MO) separates VOCs according to size and polarity. VOCs elute from the GC column and are detected on a heated metal-oxide gas sensor controlled by an electronic circuit monitored by computer software. VOCs cause a change in electrical resistance of the circuit, which is recorded at 0.5-second intervals for 40 minutes per sample.
The resistance profiles produced by the Odoreader were analyzed by an in-house-developed computer pipeline. The Odoreader platform was applied to detect patterns of VOCs able to predict response to: (1) LFD or probiotics using baseline samples; and (2) LFD or probiotics using end-of-treatment samples. The pipeline is described in depth by Aggio et al. 18 In summary, the Odoreader produces profiles of the sensor resistance vs time, or chromatograms; the characteristics of the resistance vs time create patterns that can be used to build models. The pattern is made up of a series of features. The pipeline performs chromatogram alignment, extracts wavelet coefficients, and applies other data transformation techniques that improve the detection of volatile chemical patterns specific to each group, in this case responders and non-responders. Two random forest-based algorithms were applied to select the features that best describe the differences between responders and non-responders. 17, 18 The selected features were submitted to partial least squares (PLS) statistical modeling technique to classify unknown samples. Classification results were validated using 10-fold cross-validation repeated 15 times, and principal component analysis (PCA) was applied to the transformed data. 20 The VOC extraction was undertaken in a blinded manner such that the samples were labeled using codes. The technician had no access to any clinical outcome data. For data analysis, the whole data analysis was automated, and every step of the analysis was applied for all the samples, independent of class.
Statistical analyses were performed solely on the data processed by the Odoreader. Demographic or clinical features were not included in statistical modeling because our goal was to build a model that relied exclusively on the VOC. Confidence intervals were calculated using bootstrapping. Data analysis was carried out using R software. 21 All authors had access to the study data and reviewed and approved the final manuscript.
Results

Clinical Response
A total of 95 patients completed the study, of whom 93 (63 women, 68%) provided sufficient fecal sample for analysis (n ¼ 86 from baseline visit and n ¼ 78 from follow-up). Of these 93 patients, 46 were randomized to LFD, 47 to sham diet, and 49 to probiotic, 44 to placebo as follows: LFD/probiotic (n ¼ 26), LFD/ placebo (n ¼ 20), sham/probiotic (n ¼ 23), and sham/placebo (n ¼ 24) ( Table 1 ). All 93 patients were classified as compliant with diet (sham, LFD), whereas 86 were classified as compliant with the supplement (3 to probiotic, 4 to placebo). All patients were included in this analysis. At the end of the study, those who were randomized to the LFD had a significantly lower total FODMAP intake (20 AE 8 g/day) compared with sham diet (33 AE 16 g/day) (P < .001).
There was no interaction between the interventions (diet/supplement) for the clinical end point (IBS-SSS) (P ¼ .425); therefore, results are presented separately for diet (LFD vs sham) and supplement (probiotic vs placebo). More patients responded to LFD (37/46, 80%) compared with sham (21/47, 45%) (P < .001), with a mean change in IBS-SSS score of -130 AE 81 and -49 AE 75 (P < .001), respectively. There was no difference in the numbers of responders between probiotic (31/49, 63%) and placebo (27/44, 61%) (P ¼ .850), and no difference in the mean change in IBS-SSS score between probiotic (-88 AE 78) and placebo (-90 AE 98) (P ¼ .921).
Volatile Organic Compound Modeling
The VOC patterns showed clear separation between responders and non-responders to both LFD and probiotic at both baseline and end-of-treatment. The PCAs identified: (1) 15 compounds at baseline that explained 25% of variation in response to LFD and 10 compounds that explained 30% of variation in response to probiotic; and (2) 9 compounds at end-of-treatment that explained 31% of variation in response to LFD and 11 compounds that explained 27% of variation in response to the probiotic (Figure 1 ).
The PLS model used to classify responders and nonresponders on baseline samples showed very high accuracy for both interventions. The PLS model from the LFD group predicted response to the diet with median accuracy, sensitivity, and specificity of 100% (Table 2) . However, the same LFD baseline PLS model showed low accuracy when classifying baseline samples from the patients in the control group (sham/placebo) ( Table 3) , indicating that the model was specific to response to the LFD/probiotic rather than merely response per se.
Similarly, the PLS model on baseline samples from the probiotic group predicted response to probiotic with median accuracy of 89%, median sensitivity of 100%, and median specificity of 75% (Table 2) . Again, the probiotic baseline PLS model showed low accuracy when classifying baseline samples from the control group (Table 3) .
The PLS models on end-of-treatment samples also showed high accuracy for both interventions. The PLS model from the LFD group predicted response to the diet with median accuracy, sensitivity, and specificity of 100%, and the model from the probiotic group predicted response with median accuracy of 89% and sensitivity and specificity of 100% (Supplementary Table 1) .
Although matching unique features to individual compounds is outside the scope of the Odoreader platform, one of the selected features from the end-oftreatment samples was shared across predicting response to both the LFD and probiotic intervention.
Discussion
Dietary intervention can be an effective management strategy for IBS, but little is known regarding who will, and will not, respond. This study measured VOC in baseline fecal samples, and through building separate models using key features of VOC profiles, it could correctly predict response to the LFD in 100% and to probiotic in 89% of patients. VOC may serve as a low cost, noninvasive tool that may pave the way for personalized treatment in IBS.
To our knowledge, only 3 studies have investigated predictors of response to the LFD in IBS, and all involved analysis of the microbiota or their metabolites. The first was a 2-day crossover, feeding trial in children, which showed that that at baseline, responders were enriched in Bacteroides, Ruminococcaceae, and Faecalibacterium prausnitzii, all known for saccharolytic metabolic capacity. 22 A more recent randomized controlled trial comparing the LFD with standard dietary advice 23 showed that responders to a LFD could be predicted on the basis of the baseline level of deviation from a normobiosis using a commercially available test. 24 Finally, a clinical evaluation reported that predictive factors of response to the LFD were chronic diarrhea and peak breath methane concentrations. 25 In terms of probiotics, despite the greater numbers of randomized controlled trials in IBS (compared with LFD), 14, 26 no other study has investigated response to probiotic in IBS.
There are challenges in comparing findings from these previous studies with our own. First, these studies included different potential markers, and therefore on completion, the resulting predictive model contained vastly different biomarkers of response. Second, response has been defined differently in the various studies, including meeting the minimally clinically important difference on the IBS-SSS 23 of >50 points (as used here), a >50% reduction in abdominal pain frequency, 22 and adequate symptom relief. 25 Nonetheless, the current study is consistent with identifying microbiota and their metabolites as important in predicting response. The limitations of previously identified biomarkers include cost and time burden associated with microbiota analysis and the lack of standardized pre-test preparation and 
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methodology associated with breath testing. Although VOC profiling is a relatively new technique, it may have numerous advantages over directly measuring the microbiome or single metabolites, because once a sampling protocol is developed, it could be analyzed in center and be widely and rapidly available at one-fifth of the current cost of microbial sequencing techniques. Clinical trials indicate that LFD is effective in 50%-80% of patients. However, predicting response is clinically important because the diet requires intensive dietary counselling and impacts on both the gut microbiota and nutrient intake, 11 and therefore, avoiding this intervention in the 20%-50% who are unlikely to respond would be an important clinical advance. In contrast, probiotics are widely accessible and comparatively easy to adhere to and have no known impact on nutrient intake and therefore pose less of a burden than a LFD. Nonetheless, the negative connotations associated with a failed therapy, such as loss of patient trust, in addition to the costs associated with unnecessary probiotic use reinforces the value of a biomarker that predicts response across both interventions.
There are several possible explanations why VOC patterns could predict response to the LFD. Many VOCs are created from bacterial metabolism of indigestible food substrates that reach the colon, representing both microbial metabolic activity and diet. 27, 28 Therefore, VOC patterns at baseline may reflect the (patho)physiology of an individual's IBS. For instance, eating a "normal" diet, naturally high in FODMAPs, in the presence of IBSassociated dysbiosis may generate specific products of fermentation that give rise to symptoms. Once the normal diet has been replaced by a LFD, there is less substrate for bacterial metabolism; consequently, gas production and the associated symptoms are reduced. 29 On the basis of this hypothesis, only people with the saccharolytic-rich, IBS-associated dysbiosis eating a high FODMAP diet may exhibit the specific VOC pattern predictive of response.
Similarly, with the probiotic intervention, only patients whose symptoms are triggered by IBS-associated dysbiosis in theory may respond to the probiotic intervention. Interestingly, microbial dysbiosis has been shown in approximately 60% of IBS cases, 30 which reflects the probiotic response rate observed in this study. Nonetheless, validating these models in an independent sample is warranted to confirm the predictive potential of baseline VOC patterns. The probiotic model built in the current study was based on response to a multi-strain probiotic formulation. Probiotics vary in their microbiological characteristics and their physiological and clinical impact in IBS, and it is therefore unknown whether the same model would predict response to a different probiotic.
In addition to the predictive nature of the baseline VOC patterns, the end-of-treatment models may provide additional insight into the pathophysiology of symptom generation and mechanisms underpinning dietary intervention. This study identified unique VOC patterns at follow-up that maximally separated responders and nonresponders. This suggests a divergence in microbial metabolic activity between those who experience success or failure with the intervention. The reason for the divergence may reflect either dietary compliance or true interindividual variations that may relate to the underlying drivers of IBS such as dysbiosis. Nevertheless, investigating the key features within the VOC profile may hold important clues into the mechanism of action underpinning respective dietary interventions. One of the predictive features identified in this study was shared across responders to both the LFD and probiotic, suggesting some commonalities in mechanisms. Identifying the features is outside the scope and capability of the Odoreader. Ongoing research is underway using GC-MS to identify the features that both predict and result in a clinical response.
Despite the promising nature of this research, several limitations are worthy of consideration. First, its novel nature means there was no data to inform a power calculation, and it should be viewed as an exploratory study with the data generated used to inform future external validation studies powered to detect differences in the features identified here. Second, although the predictive models demonstrated high accuracy, specificity, and sensitivity, external validation in a new, larger cohort of IBS patients is needed to determine the clinical validity of this work. Third, the purpose of the Odoreader is to identify patterns of VOCs, not individual VOCs. Although this limitation enables the tool to be time-and cost-efficient, it limits detailed investigation of the potential mechanisms linked to individual VOCs. Finally, it is feasible that the 2 Â 2 factorial design utilizing 2 interventions (LFD, probiotics, both, neither) may have clouded the results. Nonetheless, there was no interaction between interventions, meaning they did not have a synergistic or antagonistic effect on clinical response. Furthermore, it is common in the clinical setting for patients to follow multiple interventions (eg, LFD and probiotics); therefore, the fact that VOC profile could predict response to one intervention despite some patients also receiving an additional intervention is testament to the potential clinical utility.
In summary, this exploratory study suggests that fecal VOC profiling is a promising noninvasive tool that may not only help predict response to dietary interventions but also opens up a new opportunity to better understand the pathophysiology of IBS and mechanisms underpinning therapeutic response. This low-cost tool has the potential to help advance the clinical management of IBS, paving the way forward for personalized nutrition.
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Dietary Intervention
The LFD involves restricting dietary intake of fructans, galacto-oligosaccharides, lactose, fructose in excess of glucose, and polyols and is described elsewhere. 1 The sham diet was designed for this trial and restricted a similar number of staple and non-staple foods, required a similar intensity and duration of dietary counseling and similar difficulty of dietary change to the LFD, and did not impact on intakes of nutrients, fiber, and FODMAPs. 2 Dietary compliance was measured weekly by self-report during weekly telephone calls. Patients were considered compliant if they reported following the diet !50% of the time on at least 2 of the 4 weekly assessments in line with previous work. 
Clinical Outcomes
Symptoms were measured at baseline and follow-up by using the IBS-SSS. 4 The primary outcome of the parent study used the global symptom questionnaire to define response, which requires synthesis of the totality of patient symptoms into a single binary response. 5 However, because the focus of this predictive work was the clinical setting, the IBS-SSS multi-item instrument was deemed to be a more clinically meaningful outcome to measure in the current study because it combines 4 individual components: abdominal pain, distention, bowel habit, and interference with life. In addition, a reduction from baseline of !50 points on the IBS-SSS is widely accepted as a minimally clinically important difference to define patients as responders. 4 Patients with a change of <50 on the IBS-SSS were defined as non-responders. 
